ReviewEuropean journal of heart failure2009
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
Review in European journal of heart failure, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 1 synthesis or guideline pooled it, 327 citations in OpenAlex.
- Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2012Pooled it
- Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution.Basic research in cardiology · 2016Trial
- Trial
- Nutrition intervention to decrease symptoms in patients with advanced heart failure.Research in nursing & health · 2013Trial
- Lycopene dietary intervention: a pilot study in patients with heart failure.The Journal of cardiovascular nursingTrial
- Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Identification and multi-layered validation of seven diagnostic biomarkers for dilated cardiomyopathy via integrative machine learning, single-cell transcriptomics, and Mendelian randomization.Frontiers in cell and developmental biology · 2026Article
- NLRP3 inflammasome pathway activation is associated with cardiac remodeling, gut microbiota dysbiosis, and dietary protein restriction in a rat heart failure model: an integrative exploratory analysis.Frontiers in genetics · 2026Article
- Joint Associations of High-Sensitivity C-Reactive Protein and Albumin with Incident Heart Failure: A Prospective Cohort Study.Journal of inflammation research · 2026Article
- Decoding the Inflammatory Pathway in Heart Failure: The Role of Interleukins and Tumor Necrosis Factor-Alpha in Disease Severity.Journal of clinical medicine · 2025Article
- Interpretable machine learning coupled to spatial transcriptomics unveils mechanisms of macrophage-driven fibroblast activation in ischemic cardiomyopathy.medRxiv : the preprint server for health sciences · 2025Article
- Benefits of intravenous iron supplementation in heart failure.Global cardiology science & practice · 2024Article
- The role of NLRP3 inflammasome in aging and age-related diseases.Immunity & ageing : I & A · 2024Review
- Role of copper homeostasis and cuproptosis in heart failure pathogenesis: implications for therapeutic strategies.Frontiers in pharmacology · 2024Review
- Targeting Key Inflammatory Mechanisms Underlying Heart Failure: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Reduced numbers of regulatory T cells in chronic heart failure seems not to be restored by cardiac resynchronization therapy.BMC cardiovascular disorders · 2023Article
- The Predictive Values of White Blood Cell Indices (Lymphocyte and Eosinophilic Granulocyte) for Heart Failure in Acute Coronary Syndrome Patients Following Percutaneous Coronary Intervention: A Prospective Cohort Study.Clinical interventions in aging · 2023Article
- Infusion of two-dose mesenchymal stem cells is more effective than a single dose in a dilated cardiomyopathy rat model by upregulating indoleamine 2,3-dioxygenase expression.Stem cell research & therapy · 2022Article
- Development and verification of the nomogram for dilated cardiomyopathy gene diagnosis.Scientific reports · 2022Article
- An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.International journal of molecular sciences · 2022Review
80 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 1 institution in 1 country.
Funding
Abstract
The increasing prevalence of heart failure poses enormous challenges for health care systems worldwide. Despite effective medical interventions that target neurohumoral activation, mortality and morbidity remain substantial. Evidence for inflammatory activation as an important pathway in disease progression in chronic heart failure has emerged in the last two decades. However, clinical trials of 'anti-inflammatory' therapies (such as anti-tumor necrosis factor-alpha approaches) have to date failed to show benefit in heart failure patients. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop to address the issue of inflammation in heart failure from a basic science, translational and clinical perspective, and to assess whether specific inflammatory pathways may yet serve as novel therapeutic targets for this condition. This consensus document represents the outcome of the workshop and defines key research questions that still need to be addressed as well as considering the requirements for future clinical trials in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.